References
- Kiberstis PA. A surfeit of suspects. Science 2005; 307: 369.
- Tang Y, Osawa H, Onuma H, Nishimiya T, Ochi MA, Makino H. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 1999; 48: 1830–5.
- Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptor: from genes to physiology. Recent Prog Horm Res 2001; 56: 239–65.
- Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302: 93–109.
- Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336–48.
- Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003; 52: 910–17.
- Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827–31.
- Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87:2784–91.
- Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52:1364–70.
- Jiang GQ, Yang QD, Li ZH, Szalkowski D, Liu F, Shen XL, et al. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARγ agonists. Diabetes 2002;51:2412–19.
- Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, et al. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 2003; 52:1311–18.
- Page RL 2nd, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 2003;23:945–54.
- Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003;26: 2983–9.
- Kolasa T, Brooks DW. Practical synthesis of 2-Acetylbenzo[b]thiophene. Synth Commun 1993;23:743–8.
- Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, et al. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob Mice. Diabetes 1990; 39:1218–27.
- Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004;53:S215–19.
- Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. β-Cell adaptation and decompensation during the progression of diabetes. Diabetes 2001;50:S154–9.
- Porte D Jr, Kahn SE. β-Cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001;50:S160–3.
- U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–58.
- Rudenski AS, Matthews DR, Levy JC, Turner R. Understanding “insulin resistance”: both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991;40:908–17.
- Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1:165–72.
- Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, et al. Expression of peroxisome proliferator activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000;43:1165–9.
- Nesher R, Cerasi E. Modeling phasic insulin release: immediate and time-dependent effects of glucose. Diabetes 2002;51:S53–9.
- Pørksen N, Hollingda M, Juhl C, Butler P, Veldhuis JD, Schmitz O. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes 2002;51:S245–54.